This is the first study to identify a potential treatment option for patients who suffer from this variation of irritable bowel syndrome (IBS). The findings were presented at Digestive Disease Week 2006.
IBS is a dysmotility and sensory disorder characterized by abdominal pain or discomfort, bloating, and altered bowel function. IBS patients are classified based on their primary bowel complaint as either IBS with constipation (IBS-C) or IBS with diarrhea (IBS-D).
Those IBS sufferers who do not fulfill scientifically based standards for either IBS-C or IBS-D can exhibit a mixed bowel pattern, or IBS-Mixed (IBS-M). A recent study of IBS sufferers published in the journal Gastroenterology revealed that nearly one third of participants experienced IBS-M.
“These study results are promising as Zelnorm was shown to provide a statistically significant improvement in satisfactory relief of IBS symptoms in both the IBS-C and IBS-M groups. More than 50% of the IBS-M patients experienced a response to tegaserod.”
Zelnorm is approved by the FDA for chronic idiopathic constipation and IBS with constipation.